Back to search
FDAFDA · Food and drugs·Recall number D-1144-2022

medroxyPROGESTERone Acetate Injectable Suspension, USP, 1 mL Prefilled Syringe, 150 mg/mL, Rx only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured by: Sun Pharmaceutical Industries Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, NDC 16714-999-01.

Published June 22, 2022 · Recall initiated: May 6, 2022

Summary

FDA records drug Class II recall D-1144-2022, published June 22, 2022 and initiated May 6, 2022. Recalling firm: SUN PHARMACEUTICAL INDUSTRIES INC; Status: Terminated; Reported quantity: 57997 syringes; Lot: Lot#: HAC1289A, Exo 06/2023; JKX2679A, Exp 06/2022; JKX3762A, Exp 08/2022; HAC0164A, Exp 06/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of assurance of sterility

What to do

Voluntary: Firm initiated

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
SUN PHARMACEUTICAL INDUSTRIES INC
Distributor
USA Nationwide
Lot
Lot#: HAC1289A, Exo 06/2023; JKX2679A, Exp 06/2022; JKX3762A, Exp 08/2022; HAC0164A, Exp 06/2023.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was medroxyPROGESTERone Acetate Injectable Suspension, USP, 1 mL Prefilled Syringe, 150 mg/mL, Rx only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured by: Sun Pharmaceutical Industries Ltd., Halol-Baroda Highway, Halol-389 350, Gujarat, India, NDC 16714-999-01. recalled?

Yes. FDA published recall D-1144-2022 on June 22, 2022. Reported hazard: Lack of assurance of sterility

What should I do if I have this product?

Voluntary: Firm initiated